Market-Moving News for April 25th
$CDTX
$OPTN
$ULBI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CDTX alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/17/2025 | Overweight → Equal-Weight | Morgan Stanley | ||
| 11/17/2025 | Overweight → Neutral | Analyst | ||
| 11/17/2025 | Outperform → Sector Perform | RBC Capital Mkts | ||
| 10/16/2025 | $190.00 | Overweight | Morgan Stanley | |
| 10/10/2025 | $200.00 | Overweight | Analyst | |
| 6/18/2025 | $41.00 | Buy | H.C. Wainwright | |
| 3/20/2025 | Buy → Hold | Lake Street | ||
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform
Analyst downgraded Cidara Therapeutics from Overweight to Neutral
Morgan Stanley downgraded Cidara Therapeutics from Overweight to Equal-Weight
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"). "The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet," said Robert M. Davis, chairman and chief executive officer, Merck. "CD388, a potentially first-in-class, long-acting antiviral with strain-agnostic properties, underscores that approach. We look forward to building on Cidara's progress a
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has reached target enrollment in its Phase 3 ANCHOR trial of 6,000 participants across clinical trial sites in the US and UK. The trial is designed to evaluate the safety and efficacy of CD388, a non-vaccine preventative of seasonal influenza, in populations at high-
NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024GAAP EP
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
15-12G - Cidara Therapeutics, Inc. (0001610618) (Filer)
EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024GAAP EP
NEWARK, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 18, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7b
Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak® platform
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)